Fig. 2.

Detection of KRAS mutations in plasma of patients with pancreatic cancers. (a) Comprehensive analysis of cfDNA-based measurements of KRAS mutations in 13 previous reports. (b) ctDNA and KRAS hotspot mutations detected in cancer patients using SLHC-Seq. Diagnosis of PDAC using detection of mutations in (c) KRAS gene or (d) a combination of KRAS, CDKN2A, TP53 and SMAD4. (e) Heatmap is presented to illustrate the KRAS mutational heterogeneity in plasma ctDNA. Colour scale of each square represents the allele frequency of mutations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)